X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4059) 4059
Publication (453) 453
Newsletter (176) 176
Book Review (69) 69
Book Chapter (16) 16
Book / eBook (10) 10
Data Set (6) 6
Dissertation (5) 5
Conference Proceeding (3) 3
Newspaper Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (3323) 3323
pharmacology & pharmacy (2668) 2668
index medicus (2119) 2119
male (1966) 1966
pharmacokinetics (1615) 1615
drug interactions (1493) 1493
female (1319) 1319
adult (1214) 1214
cytochrome p-450 cyp3a (1181) 1181
metabolism (1119) 1119
cytochrome p-450 enzyme system - metabolism (1116) 1116
animals (1084) 1084
cytochrome p-450 cyp3a - metabolism (1053) 1053
cytochrome p-450 (1004) 1004
middle aged (902) 902
cytochrome p-450 enzyme inhibitors (711) 711
in-vitro (651) 651
area under curve (623) 623
rats (600) 600
cytochrome p-450 cyp3a - genetics (580) 580
research (577) 577
cytochrome p450 (568) 568
cytochrome p-450 cyp3a inhibitors (558) 558
p-glycoprotein (548) 548
cyp3a4 (503) 503
microsomes, liver - metabolism (501) 501
toxicology (488) 488
enzyme inhibitors - pharmacology (482) 482
administration, oral (476) 476
microsomes, liver - enzymology (474) 474
genotype (465) 465
enzymes (459) 459
inhibition (444) 444
human liver-microsomes (443) 443
dose-response relationship, drug (416) 416
aged (409) 409
pharmacogenetics (400) 400
microsomes, liver - drug effects (395) 395
young adult (394) 394
physiological aspects (391) 391
biotransformation (368) 368
pharmacology (367) 367
analysis (366) 366
cytochrome p-450 enzyme system - genetics (358) 358
cross-over studies (354) 354
expression (347) 347
liver (341) 341
midazolam (329) 329
drug-interactions (325) 325
kinetics (320) 320
pharmacology/toxicology (317) 317
ketoconazole (313) 313
rats, sprague-dawley (307) 307
metabolites (302) 302
cyp3a (291) 291
adolescent (290) 290
ketoconazole - pharmacology (276) 276
genetic aspects (272) 272
biological availability (269) 269
chromatography, high pressure liquid (261) 261
drug-drug interactions (260) 260
half-life (260) 260
midazolam - pharmacokinetics (259) 259
tacrolimus (258) 258
drug metabolism (257) 257
models, biological (255) 255
cytochrome (251) 251
mixed function oxygenases - metabolism (249) 249
induction (248) 248
health aspects (243) 243
aryl hydrocarbon hydroxylases - metabolism (241) 241
cancer (241) 241
aryl hydrocarbon hydroxylases (238) 238
liver - metabolism (238) 238
drugs (237) 237
in vitro techniques (236) 236
liver - enzymology (235) 235
dosage and administration (231) 231
hydroxylation (226) 226
drug interaction (223) 223
cyclosporine (221) 221
immunosuppressive agents - pharmacokinetics (218) 218
mice (218) 218
drug therapy (217) 217
biochemistry & molecular biology (214) 214
polymorphism, genetic (214) 214
oncology (203) 203
pharmacodynamics (203) 203
time factors (200) 200
bioavailability (199) 199
liver - drug effects (198) 198
mixed function oxygenases - antagonists & inhibitors (196) 196
identification (193) 193
cytochrome p-450 cyp2c19 (191) 191
genetic polymorphisms (190) 190
grapefruit juice (184) 184
chemistry, medicinal (182) 182
drug-drug interaction (181) 181
article (179) 179
cyp3a5 (179) 179
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4194) 4194
Spanish (27) 27
Chinese (9) 9
German (9) 9
Japanese (9) 9
French (6) 6
Russian (4) 4
Polish (2) 2
Czech (1) 1
Danish (1) 1
Finnish (1) 1
Italian (1) 1
Norwegian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Drug Metabolism and Disposition, ISSN 0090-9556, 02/2015, Volume 43, Issue 2, pp. 182 - 189
Evaluation of drug-drug interaction (DDI) involving circulating inhibitory metabolites of perpetrator drugs has recently drawn more attention from regulatory... 
IN-VITRO | WARFARIN | KINETICS | HUMANS | PHARMACOLOGY & PHARMACY | PLASMA-PROTEIN BINDING | DESETHYLAMIODARONE | DISCOVERY | DIALYSIS | Cytochrome P-450 CYP2D6 Inhibitors - chemistry | Liver - enzymology | Cytochrome P-450 CYP2D6 Inhibitors - metabolism | Expert Systems | Humans | Middle Aged | Cytochrome P-450 CYP3A Inhibitors - pharmacokinetics | Male | Cytochrome P-450 CYP2C9 Inhibitors - chemistry | Amiodarone - blood | Anti-Arrhythmia Agents - metabolism | Amiodarone - administration & dosage | Dose-Response Relationship, Drug | Young Adult | Drug Interactions | Liver - drug effects | Amiodarone - pharmacokinetics | Computer Simulation | Cytochrome P-450 CYP3A Inhibitors - chemistry | Cytochrome P-450 CYP2C9 Inhibitors - metabolism | Adult | Female | Cytochrome P-450 CYP2C9 Inhibitors - blood | Reproducibility of Results | Cytochrome P-450 CYP2D6 Inhibitors - pharmacokinetics | Cytochrome P-450 CYP3A Inhibitors - blood | Administration, Oral | Liver - metabolism | Amiodarone - antagonists & inhibitors | Anti-Arrhythmia Agents - chemistry | Anti-Arrhythmia Agents - pharmacokinetics | Anti-Arrhythmia Agents - administration & dosage | Amiodarone - analogs & derivatives | Amiodarone - metabolism | Cytochrome P-450 CYP3A Inhibitors - metabolism | Models, Biological | Biotransformation - drug effects | Cytochrome P-450 CYP2D6 Inhibitors - blood | Infusions, Intravenous | Cytochrome P-450 CYP2C9 Inhibitors - pharmacokinetics
Journal Article
Journal of Medicinal Chemistry, ISSN 0022-2623, 08/2017, Volume 60, Issue 15, pp. 6678 - 6692
Porcupine is an O-acyltransferase that regulates Wnt secretion. Inhibiting porcupine may block the Wnt pathway which is often dysregulated in various cancers.... 
TARGET | CHEMISTRY, MEDICINAL | PATHWAY | MECHANISMS | BETA-CATENIN | WNT | CANCER | Acyltransferases - antagonists & inhibitors | Maleimides - administration & dosage | Cytochrome P-450 CYP3A Inhibitors - pharmacology | Antineoplastic Agents - chemical synthesis | Humans | Microsomes, Liver - metabolism | Maleimides - pharmacology | Cytochrome P-450 CYP3A Inhibitors - pharmacokinetics | Structure-Activity Relationship | Antineoplastic Agents - administration & dosage | Pyridazines - pharmacology | Pyridazines - chemical synthesis | Maleimides - pharmacokinetics | Cytochrome P-450 CYP1A2 Inhibitors - pharmacokinetics | Maleimides - chemical synthesis | HEK293 Cells | Pyridazines - administration & dosage | Female | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - pharmacology | Cytochrome P-450 CYP2D6 Inhibitors - pharmacology | Wnt Signaling Pathway | Cytochrome P-450 CYP2D6 Inhibitors - pharmacokinetics | Cytochrome P-450 CYP3A Inhibitors - administration & dosage | Rats | Cytochrome P-450 CYP1A2 Inhibitors - chemical synthesis | Cytochrome P-450 CYP2D6 Inhibitors - administration & dosage | Cytochrome P-450 CYP3A Inhibitors - chemical synthesis | Xenograft Model Antitumor Assays | Animals | Cytochrome P-450 CYP1A2 Inhibitors - pharmacology | Cytochrome P-450 CYP2D6 Inhibitors - chemical synthesis | High-Throughput Screening Assays | Membrane Proteins - antagonists & inhibitors | Mice, Nude | Cytochrome P-450 CYP1A2 Inhibitors - administration & dosage | Cell Line, Tumor | Pyridazines - pharmacokinetics | Mice, Inbred BALB C
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 09/2015, Volume 55, Issue 9, pp. 1012 - 1023
Journal Article
Journal Article
European Journal of Clinical Pharmacology, ISSN 0031-6970, 7/2018, Volume 74, Issue 7, pp. 913 - 920
Journal Article
Journal Article
Journal Article
Journal Article
Journal Article
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 02/2018, Volume 103, Issue 2, pp. 287 - 295
Journal Article
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 08/2014, Volume 54, Issue 8, pp. 949 - 957
This study compared the bioavailability of two candidate fixed-dose combinations (FDCsG003 and G004) of darunavir/cobicistat 800/150 mg with that of darunavir... 
fixed‐dose combination | darunavir | cobicistat | bioavailability | pharmacoenhancer | fixed-dose combination | EFFICACY | SAFETY | HIV-1-INFECTED PATIENTS | ANTIRETROVIRAL THERAPY | PROTEASE INHIBITORS | TREATMENT-NAIVE | HIV | TREATMENT-EXPERIENCED PATIENTS | PHARMACOLOGY & PHARMACY | LOPINAVIR/RITONAVIR | ONCE-DAILY DARUNAVIR/RITONAVIR | Thiazoles - blood | Darunavir | Humans | Middle Aged | Biological Availability | Cytochrome P-450 CYP3A Inhibitors - pharmacokinetics | Male | Thiazoles - administration & dosage | Carbamates - administration & dosage | Healthy Volunteers | Carbamates - pharmacokinetics | Thiazoles - adverse effects | Thiazoles - pharmacokinetics | Young Adult | Sulfonamides - blood | Ritonavir - adverse effects | HIV Protease Inhibitors - pharmacokinetics | Adult | Female | HIV Protease Inhibitors - adverse effects | HIV Protease Inhibitors - blood | Cytochrome P-450 CYP3A Inhibitors - administration & dosage | Cytochrome P-450 CYP3A Inhibitors - blood | Ritonavir - administration & dosage | Ritonavir - blood | Carbamates - blood | HIV Protease Inhibitors - administration & dosage | Sulfonamides - pharmacokinetics | Cross-Over Studies | Ritonavir - pharmacokinetics | Sulfonamides - adverse effects | Carbamates - adverse effects | Cytochrome P-450 CYP3A Inhibitors - adverse effects | Cobicistat | Drug Combinations | Sulfonamides - administration & dosage | Usage | Dosage and administration | Drug therapy, Combination | Pharmacokinetics | Analysis | Short term
Journal Article
Journal Article
Journal of Thrombosis and Haemostasis, ISSN 1538-7933, 02/2017, Volume 15, Issue 2, pp. 273 - 283
Journal Article